BioCryst Pharmaceuticals (BCRX) in Focus: Stock Moves 8.5% HigherZacks Investment Research • 02/28/20
BioCryst Submits Japanese New Drug Application for Oral, Once Daily BerotralstatGlobeNewsWire • 02/03/20
BioCryst Submits New Drug Application for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE AttacksGlobeNewsWire • 12/11/19
BioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common StockGlobeNewsWire • 11/18/19
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/06/19
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/06/19
New Clinical Trial Results and Market Research Support Significant Commercial Opportunity for Oral, Once Daily BCX7353 in HAEGlobeNewsWire • 11/06/19